CEL-SCI study in Oral Oncology flags low PD-L1, N0 oral cancer patients for Multikine survival benefit
CVM•Oral Oncology study highlights biomarker-defined Multikine benefit
CEL-SCI published peer-reviewed results in Oral Oncology from its IT-MATTERS trial; results were already presented in the journal publication.
- The study supports using low or zero PD-L1 expression and no lymph node involvement to identify oral cancer patients most likely to benefit from Multikine.
- Biomarker-selected patients treated with Multikine before surgery showed better survival outcomes than standard care alone, supporting a differentiated positioning versus checkpoint inhibitors.
- Enrollment is being prepared for a 212-patient global confirmatory registration study in the same biomarker-defined population to validate the earlier survival benefit.
